Azurity Pharmaceuticals, Inc. Announces the Availability of BRYNOVIN™ (sitagliptin), the First and Only Oral Liquid Sitagliptin
BRYNOVIN, which was approved by the U.S. Food and Drug Administration (FDA) in January 2025, is the first and only oral liquid sitagliptin for the management of type 2 diabetes mellitus in adults in conjunction with diet and exercise.1
'BRYNOVIN demonstrates our commitment to breaking down barriers to patient care by providing sitagliptin in an oral liquid solution for adult patients with T2DM that may have difficulty swallowing pills or may have needle fear that affects treatment adherence,' said Ron Scarboro, CEO at Azurity Pharmaceuticals. 'Building on our longstanding legacy in dose form innovations, we continue to rapidly grow our capabilities in this space and deliver on our purpose to serve overlooked patients.'
With more than 38 million Americans living with diabetes2, and 90-95% of them diagnosed with type 2 diabetes, there remains a significant need for alternative treatment options3. For many, especially older adults and those in long-term care facilities, swallowing pills is a daily challenge that may lead to poor adherence and compromised outcomes4,5.
BRYNOVIN provides effective HbA1c control as an adjunct to diet and exercise when used as monotherapy or in combination with other antihyperglycemic agents in adults with type 2 diabetes mellitus. The recommended dose of BRYNOVIN is 100 mg (25 mg/mL), administered as 4 mL once daily. BRYNOVIN is not recommended in patients with type 1 diabetes and has not been studied in patients with a history of pancreatitis. For full prescribing information, please visit brynovin.com.
1. U.S Food and Drug Administration Orange Book. Accessed July 21, 2025. https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm2. Centers for Disease Control and Prevention (CDC). Type 2 Diabetes. Accessed July 17, 2025 https://www.cdc.gov/diabetes/about/about-type-2-diabetes.html3. Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report 2024. https:// www.cdc.gov/diabetes/php/data-research/methods.html?CDC_AAref_Val=https://www.cdc.gov/diabetes/data/statistics-report4. Wittenberg E, et al. 'Medication Adherence in Older Adults: A Qualitative Study.' Patient Preference and Adherence. 2019;13:1443–1450.5. Schiele J et al 'Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms' Eur J Clinical Pharmacol (2013) 69:937-948
About Azurity Pharmaceuticals:Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity's global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people. For more information, including prescribing information, visit www.azurity.com.
©2025 Azurity Pharmaceuticals, Inc.
PP-BRN-US-0029
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
2 days ago
- Malay Mail
US notes drop in junk food consumption, but ultra-processed food like burgers and sodas still dominates diets
WASHINGTON, Aug 8 — Americans still get most of their calories from ultra-processed foods, but consumption is trending down among both adults and children, official data showed yesterday. The survey results from the Centers for Disease Control and Prevention come as Health Secretary Robert F. Kennedy Jr. promotes diet reform — and suggest that awareness of the risks around burgers and sodas may already have been taking hold before he came to office. Between August 2021 to August 2023, the mean percentage of total calories consumed from ultra-processed foods (UPFs) among those aged one year and older was 55 percent. That still places the United States at or near the top of the table globally, alongside countries like the United Kingdom and Canada. Among Western nations, Italy consistently records lower UPF consumption — less than 20 percent, according to a paper published in 2021 in Public Health Nutrition that credited the Mediterranean diet. Breaking down the new US results by age, the percentage of energy consumed from UPFs was 61.9 percent for youths aged one to 18, and 53.0 percent for adults — a decline from 65.6 percent and 56.0 percent respectively during the last survey period, 2017-18. Former first lady Michelle Obama spearheaded a campaign in the 2010s to encourage healthier eating and more exercise, while a landmark 2019 study in Cell Metabolism found people ate more calories when exposed to ultra-processed foods. Ultra-processed foods tend to be 'hyperpalatable, energy-dense, low in dietary fibre, and contain little or no whole foods, while having high amounts of salt, sweeteners, and unhealthy fat,' according to the CDC. They have been linked with ill health effects including higher risk of cardiovascular disease and all-cause mortality. A study published in Nature this week randomised 55 adults in the UK who were overweight or obese to eat either minimally-processed food (MPF) diets or UPF — with significantly greater weight loss in the MPF group after eight weeks. Sandwiches, including burgers, topped the list of UPFs for both US youth and adults, followed by sweet bakery products such as donuts. Sweetened beverages were high up on both lists. Since taking office, Kennedy has launched a pressure campaign on industry to remove synthetic food dyes, which appears to be paying dividends, with cereal maker Kellogg's one of the latest brands to sign on. A dozen states meanwhile have moved to restrict access of people with Supplemental Nutrition Assistance Program benefits — known colloquially as food stamps — to junk food at grocery stores. — AFP
Malaysian Reserve
2 days ago
- Malaysian Reserve
Governor Glenn Youngkin Announces $3 Million Grant to Support Civica's Affordable Insulin Programs
PETERSBURG, Va., Aug. 7, 2025 /PRNewswire/ — Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes. 'We are proud to partner with Civica in their mission to make essential medicines more accessible,' said Governor Youngkin. 'This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities.' These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin. The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to 'accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development.' 'We are grateful for the Commonwealth's support,' said Ned McCoy, Civica's President and CEO. 'This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs.' Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization. 'More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication,' said Starr. 'Civica's work will help to make insulin more affordable for people across the country.' Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins. Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status. About CivicaCivica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients. Media Contact:Liz 860 501 3849 1 Facility prior approval inspection expected in 2026.
Malaysian Reserve
5 days ago
- Malaysian Reserve
Nuna Selected by White House and CMS to Join Landmark Health Tech Ecosystem Initiative
SAN FRANCISCO, Aug. 4, 2025 /PRNewswire/ — Nuna announced its selection to join the Centers for Medicare & Medicaid Services (CMS) Health Tech Ecosystem, a landmark public-private initiative designed to transform healthcare for Americans. The initiative was unveiled at a White House event on Wednesday by President Donald Trump, CMS Administrator Dr. Mehmet Oz, HHS Secretary Robert F. Kennedy Jr., and Amy Gleason, Acting Administrator of DOGE. The event was attended by a select group of healthcare leaders and innovators, including Nuna Founder and CEO, Jini Kim. As part of the ecosystem, Nuna will contribute its expertise to two cornerstone efforts: Conversational AI Assistance and Diabetes & Obesity Prevention and Management. 'We're honored to stand alongside CMS in this bold and necessary step forward in healthcare,' said Jini Kim. 'We believe health isn't just built in the hospital or clinic; it's forged in the small moments of our daily lives. That's why we created Nuna, a trusted digital companion to help people succeed on their health journey, one day at a time.' Nuna's pledge is centered on its AI-powered digital engagement platform. Nuna's app empowers patients to confidently manage their chronic conditions through a combination of 24/7 conversational support, motivating gamification, and direct linkage to their clinical care team. This integrated approach drives powerful results: 72% of users with uncontrolled hypertension achieve control and 73% remain active after six months. By connecting daily patient behavior to the clinical team, Nuna bridges a critical gap in today's healthcare landscape by enabling timely, proactive intervention by care teams for their patients. 'Nuna has been a game changer for patients struggling with chronic conditions,' said David Ansell, MD, of Rush University System for Health and a Nuna development partner. 'It extends care from the clinic to the home and its AI enhanced education engages patients in behavioral change that persists over time. The result being better blood pressure control and improved health behaviors. Early results suggest it can crack the code on chronic disease self-management by engaging people to attend to their health when they are in their homes. This type of tech innovation has great potential to transform primary and preventive care across the US.' About Nuna Nuna is a digital health company dedicated to transforming chronic care by empowering patients and their clinicians. Its AI-driven platform provides personalized, continuous support to help people manage their health and chronic conditions in the moments that matter most. Nuna partners with health systems and health plans to improve patient outcomes, enhance care team efficiency, and reduce the overall cost of care. For more information about Nuna's participation in the CMS Digital Health Ecosystem, visit or contact press@
